{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:25:14Z","timestamp":1791563114706,"version":"4.3.4"},"reference-count":0,"publisher":"Termedia Sp. z.o.o.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Med Sci"],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>In patients with breast cancer and lymphoma, anthracyclines are associated with early and late dose-related cardiotoxicity. We systematically evaluated efficacy and harms of the use of beta-blockers in breast cancer and lymphoma patients undergoing chemotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Material and methods<\/jats:title><jats:p>We searched five engines, and pre-prints until October 10, 2022, for randomised controlled trials (RCTs) evaluating beta-blockers for anthracycline-associated cardiotoxicity in breast cancer and lymphoma patients. Primary outcomes were all-cause mortality, left ventricular ejection fraction (LVEF), left ventricular end-diastolic and end-systolic diameter (LVEDD, LVESD), peak E\u2019 velocity, E\/A ratio, E\/e\u2019 ratio, NT-pro BNP levels. Secondary outcome was heart rate. Inverse variance random effect meta-analyses were performed, and we used GRADE methods to assess quality of evidence (QoE).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twelve RCTs were selected (n=1,794), seven RCTs evaluated carvedilol. Mean ages were 39 to 52 years-old, 88.5% were women; 79.4% had breast cancer, and 11.5% lymphoma. The evidence was very uncertain about the effect of beta-blockers on all-cause mortality (RR 0.87, 95%CI 0.55 to 1.37, 12 RCTs, I2=0%, very low QoE), LVEF (MD 2.73%, 95%CI -0.45% to 5.92%, 12 RCTs, I2=93%, very low QoE), and heart rate (MD -9.14 bpm, 95%CI -15.02 to -3.26, two RCTs, I2=87%, very low QoE) vs. controls. Beta-blockers likely reduced NT-pro BNP levels slightly (MD -15.35 pg\/mL, 95%CI -22.39 to -8.31, two RCTs, I2=0%, moderate QoE). There were no effects on other outcomes, all with very low QoE.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Prophylactic use of beta-blockers for cardioprotection had little to no effect on all-cause mortality, LVEF or cardiac function outcomes in cancer patients undergoing anthracycline therapy.<\/jats:p><\/jats:sec>","DOI":"10.5114\/aoms\/189501","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T20:19:39Z","timestamp":1718309979000},"source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and harms associated with beta-blockers for cardiotoxicity in cancer patients undergoing chemotherapy: a systematic review and meta-analysis."],"prefix":"10.5114","author":[{"given":"Jessica T.","family":"Li","sequence":"first","affiliation":[{"name":"University of Connecticut School of Pharmacy, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda MM.","family":"Duddy","sequence":"additional","affiliation":[{"name":"University of Connecticut School of Pharmacy, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Cardona","sequence":"additional","affiliation":[{"name":"University of Connecticut School of Pharmacy, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Pasupuleti","sequence":"additional","affiliation":[{"name":"Oxford PharmaGenesis, Inc., United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9999-4003","authenticated-orcid":true,"given":"Adrian V","family":"Hernandez","sequence":"additional","affiliation":[{"name":"University of Connecticut School of Pharmacy, United States"},{"name":"Unidad de Revisiones Sistem\u00e1ticas y Meta-an\u00e1lisis (URSIGET), Vicerrectorado de Investigaci\u00f3n, Universidad San Ignacio de Loyola., Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3061","published-online":{"date-parts":[[2024,6,13]]},"container-title":["Archives of Medical Science"],"original-title":[],"link":[{"URL":"https:\/\/www.archivesofmedicalscience.com\/pdf-189501-111188","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.archivesofmedicalscience.com\/pdf-189501-111188","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T20:19:41Z","timestamp":1718309981000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.archivesofmedicalscience.com\/Efficacy-and-harms-associated-with-beta-blockers-for-cardiotoxicity-in-cancer-patients,189501,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,13]]},"references-count":0,"alternative-id":["189501"],"URL":"https:\/\/doi.org\/10.5114\/aoms\/189501","relation":{},"ISSN":["1734-1922","1896-9151"],"issn-type":[{"value":"1734-1922","type":"print"},{"value":"1896-9151","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,13]]}}}